Aarti Pharmalabs Soars on Q1 Profit Surge

Aarti Pharmalabs experienced a significant stock surge, hitting a 20% upper circuit on Monday. This rally followed the company's announcement of a robust 65.4% year-on-year increase in its Q1 FY27 net profit, reaching Rs 76.14 crore. The company's consolidated revenue from operations also saw substantial growth, rising by 38.7% to Rs 535.79 crore in the same quarter.

Fueling future growth, Aarti Pharmalabs' Board of Directors has approved a capital expenditure of Rs 149 crore. This investment is earmarked for the construction of a new Intermediate Block, which will enhance manufacturing capacity by 405 KL. This expansion is designed to meet the increasing demand from its contract development and manufacturing organisation (CDMO) clients and is expected to be completed within one year.

In addition to financial and expansion updates, the company announced significant board-level management changes. Effective October 1, 2026, subject to shareholder approval, Shri Rashesh C. Gogri will move to Managing Director, and Smt. Hetal Gogri Gala will transition to Executive Director. These changes are part of a broader board restructuring.